Multidrug-resistant tuberculosis

CHA

Tag: Multidrug-resistant tuberculosis

India: Mumbai TB Symposium Focuses on Advancing TB Treatment and Collaboration

10 June 2024, Mumbai: A pivotal symposium organised today by Médecins Sans Frontières (MSF)/Doctors Without Borders brought together a diverse coalition of experts and stakeholders to forge actionable strategies against Drug-Resistant Tuberculosis (DRTB). This crucial gathering aimed to highlight the...

Read more

MSF calls again on J&J to withdraw or abandon extended patents on lifesaving TB drug as main patent expires in India today, opening door to more affordable generics

MSF calls again on J&J to withdraw or abandon extended patents on lifesaving TB drug as main patent expires in India today, opening door to more affordable generics. Recent deal offering controlled generics access in limited countries does not go...

Read more

TB medicine deal offers short-term solution, but J&J needs to do more for all affected countries

Christophe Perrin, TB advocacy pharmacist, MSF Access Campaign  "Today's announcement by the Stop TB Partnership/Global Drug Facility about a deal with pharmaceutical corporation Johnson & Johnson (J&J), for access to affordable generic versions of the lifesaving tuberculosis (TB) drug bedaquiline, offers...

Read more

MSF applauds Indian Patent Office’s rejection of Johnson & Johnson’s attempt to extend monopoly on lifesaving TB drug

Mumbai, 23 March 2023 – Today, the 2019 patent challenge by two tuberculosis (TB) survivors, Nandita Venkatesan and Phumeza Tisile, was successful: the Indian Patent Office rejected the US pharmaceutical corporation Johnson & Johnson’s (J&J) attempt to extend its monopoly...

Read more

Urgent need to improve access to TB testing to support rollout of better, safer, shorter treatment for drug-resistant TB

Delhi, 22 March 2023 - Médecins Sans Frontières/Doctors Without Borders (MSF) called on governments and donors today to speed up access to new, shorter, safer and more effective treatments* for drug-resistant tuberculosis (DR-TB), as well as the diagnostic tests needed...

Read more

Global TB Report 2022: MSF calls for scale up of shorter and safer DR-TB treatments to help save more lives

The World Health Organization (WHO) released today the 2022 edition of its Global Tuberculosis (TB) Report, featuring data on the TB response and trends in 215 countries and areas. Among the alarming trends from 2021, there is an increase in the estimated...

Read more

Tuberculosis: Clinical trial results offer hope to DR-TB patients with short, effective treatment

LONDON – TB-PRACTECAL, a clinical trial led by Doctors Without Borders/Médecins Sans Frontières (MSF), has found that a new, all-oral, six-month treatment regimen is safer and more effective at treating rifampicin-resistant tuberculosis (RR-TB) [1] than the currently accepted standard of care....

Read more

Tuberculosis: EndTB clinical trial for multidrug-resistant TB completes enrolment

BOSTON/PARIS — Hundreds of patient volunteers from four continents have enrolled in a trial that aims to find safer, shorter, and effective treatments for multidrug-resistant tuberculosis (MDR-TB), an airborne, infectious disease that has grown resistant to standard medications. A group of scientists and...

Read more
Show Buttons
Share On Facebook
Share On Twitter
Share On Linkedin
Contact us
Hide Buttons